The estimated Net Worth of Ronald S. Rogers is at least 105 千$ dollars as of 9 May 2014. Ronald Rogers owns over 12,500 units of Myriad Genetics stock worth over 104,594$ and over the last 12 years Ronald sold MYGN stock worth over 0$.
Ronald has made over 1 trades of the Myriad Genetics stock since 2014, according to the Form 4 filled with the SEC. Most recently Ronald exercised 12,500 units of MYGN stock worth 314,000$ on 9 May 2014.
The largest trade Ronald's ever made was exercising 12,500 units of Myriad Genetics stock on 9 May 2014 worth over 314,000$. On average, Ronald trades about 3,125 units every 0 days since 2013. As of 9 May 2014 Ronald still owns at least 3,980 units of Myriad Genetics stock.
You can see the complete history of Ronald Rogers stock trades at the bottom of the page.
Ronald's mailing address filed with the SEC is 320, Wakara Way, U of U Research Park, Salt Lake City, Salt Lake County, Utah, 84108, United States.
Over the last 22 years, insiders at Myriad Genetics have traded over 51,783,466$ worth of Myriad Genetics stock and bought 61,160 units worth 1,252,955$ . The most active insiders traders include Jerry S Lanchbury、Peter D Meldrum、Arthur H Jr Hayes. On average, Myriad Genetics executives and independent directors trade stock every 18 days with the average trade being worth of 563,312$. The most recent stock trade was executed by Heinrich Dreismann on 9 September 2024, trading 10,000 units of MYGN stock currently worth 270,500$.
myriad genetics inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. myriad is focused on three strategic imperatives: maintaining leadership in an expanding hereditary cancer market, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. for more information on how myriad is making a difference, please visit the company's website: www.myriad.com.
Myriad Genetics executives and other stock owners filed with the SEC include: